Literature DB >> 32775946

Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer.

Karen A Cadoo1,2, Diana L Mandelker3, Semanti Mukherjee1,4, Carolyn Stewart1, Deborah DeLair3, Vignesh Ravichandran1,4, Preethi Srinivasan3,5, Daire Hurley6, Yelena Kemel4, Angela G Arnold1, Margaret Sheehan1, Nisha Pradhan1, Vijai Joseph1,4, Dennis S Chi2,7, Ginger J Gardner2,7, Elizabeth L Jewell2,7, Mario M Leitao2,7, Kara Long Roche2,7, Jennifer J Mueller2,7, Yukio Sonoda2,7, Oliver Zivanovic2,7, Michael Walsh2,8, Maria I Carlo2,7, Michael F Berger2,3,5,9, David Hyman1,2, Liying Zhang3, Mark E Robson1,2,4, Kenneth Offit1,2,4, Carol Aghajanian1,2, Nadeem R Abu Rustum2,7, Zsofia Stadler1,2,4.   

Abstract

PURPOSE: Mutations in DNA mismatch repair (MMR) genes and PTEN, diagnostic of Lynch and Cowden syndromes, respectively, represent the only established inherited predisposition genes in endometrial cancer to date. The prevalence of other cancer predisposition genes remains unclear. We sought the prevalence of pathogenic germline variants in unselected patients with endometrial cancer attending for surgical consultation. PATIENTS AND METHODS: Patients were prospectively consented (4/2016-5/2017) to an IRB-approved protocol of tumor-normal sequencing via a custom next-generation sequencing panel (MSK-IMPACT) with return of germline results for >75 cancer predisposition genes. Tumors were assessed for microsatellite instability (MSI). Per institutional standards, all tumors underwent Lynch syndrome screening via IHC for MMR proteins.
RESULTS: Of 156 patients who consented to germline genetic testing, 118 (76%) had stage I disease. Tumors were endometrioid in 104 (67%), of which 60 (58%) were grade 1. Twenty-four pathogenic germline variants were identified in 22 patients (14%)-7 (4.5%) with highly penetrant cancer syndromes and 15 (9.6%) with variants in moderate-, low-penetrance, or recessive genes. Of these, 5 (21%) were in Lynch syndrome genes (2 MSH6, 2 PMS2, and 1 MLH1). All 5 tumors had concordant IHC staining; 2 (40%) were definitively MSI-high by next-generation sequencing. One patient had a known BRCA1 mutation; 1 had SMARCA4 deletion. The remaining 17 variants (71%) were incremental findings in moderate- and low-penetrance variants or genes associated with recessive disease.
CONCLUSION: In unselected patients with predominantly low-risk, early-stage endometrial cancer, germline multi-gene panel testing identifies cancer predisposition gene variants in 14%. This finding may have implications for future cancer screening and risk-reduction recommendations. Universal IHC screening for Lynch syndrome successfully identifies the majority (71%) of high-penetrance germline mutations.

Entities:  

Year:  2019        PMID: 32775946      PMCID: PMC7409950          DOI: 10.1200/po.18.00338

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  50 in total

1.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

Authors: 
Journal:  Am J Hum Genet       Date:  2004-04-30       Impact factor: 11.025

2.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

3.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?

Authors:  Susan M Domchek; Angela Bradbury; Judy E Garber; Kenneth Offit; Mark E Robson
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

4.  National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

Authors:  Christopher P Childers; Kimberly K Childers; Melinda Maggard-Gibbons; James Macinko
Journal:  J Clin Oncol       Date:  2017-08-18       Impact factor: 44.544

5.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.

Authors:  Samir Gupta; Dawn Provenzale; Scott E Regenbogen; Heather Hampel; Thomas P Slavin; Michael J Hall; Xavier Llor; Daniel C Chung; Dennis J Ahnen; Travis Bray; Gregory Cooper; Dayna S Early; James M Ford; Francis M Giardiello; William Grady; Amy L Halverson; Stanley R Hamilton; Jason B Klapman; David W Larson; Audrey J Lazenby; Patrick M Lynch; Arnold J Markowitz; Robert J Mayer; Reid M Ness; Niloy Jewel Samadder; Moshe Shike; Shajanpeter Sugandha; Jennifer M Weiss; Mary A Dwyer; Ndiya Ogba
Journal:  J Natl Compr Canc Netw       Date:  2017-12       Impact factor: 11.908

6.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.

Authors:  Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

Review 7.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

8.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

9.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

10.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25
View more
  2 in total

1.  Diagnosis and management of an endometrial cancer patient with Cowden syndrome.

Authors:  Beryl L Manning-Geist; Sonia Gatius; Ying Liu; Mabel Gil; Arnaud Da Cruz Paula; Noemi Tuset; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt; Xavier Matias-Guiu
Journal:  Gynecol Oncol       Date:  2021-08-23       Impact factor: 5.304

2.  Rare deleterious germline variants and risk of lung cancer.

Authors:  Yanhong Liu; Jun Xia; James McKay; Spiridon Tsavachidis; Xiangjun Xiao; Margaret R Spitz; Chao Cheng; Jinyoung Byun; Wei Hong; Yafang Li; Dakai Zhu; Zhuoyi Song; Susan M Rosenberg; Michael E Scheurer; Farrah Kheradmand; Claudio W Pikielny; Christine M Lusk; Ann G Schwartz; Ignacio I Wistuba; Michael H Cho; Edwin K Silverman; Joan Bailey-Wilson; Susan M Pinney; Marshall Anderson; Elena Kupert; Colette Gaba; Diptasri Mandal; Ming You; Mariza de Andrade; Ping Yang; Triantafillos Liloglou; Michael P A Davies; Jolanta Lissowska; Beata Swiatkowska; David Zaridze; Anush Mukeria; Vladimir Janout; Ivana Holcatova; Dana Mates; Jelena Stojsic; Ghislaine Scelo; Paul Brennan; Geoffrey Liu; John K Field; Rayjean J Hung; David C Christiani; Christopher I Amos
Journal:  NPJ Precis Oncol       Date:  2021-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.